NEW YORK (GenomeWeb News) – Horizon Discovery said today that Array BioPharma will use its X-MAN human isogenic cell lines to evaluate a target that could be used as a cancer treatment.
Array will evaluate a panel of the X-MAN cell lines carrying specific mutant cancer genes with matched parental genetic backgrounds. Array aims to study the potential utility of its compounds and will share some of the data it generates over the course of the evaluation period, which starts this month.
"We are rapidly getting our novel 'patient-relevant' X-MAN cancer models into real world drug discovery research programs," Darrin Disley, Horizon's chairman and commercial director, said in a statement.
Financial terms of the agreement were not released.